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The arsenical compound N-phenylglycineamide-p-arsonic acid, the toxic action of which has been described in the preceding paper, exercises a powerful therapeutic effect in experimental trypanosomiasis of laboratory animals. Trypanosomiasis as it occurs in mice and rats is chiefly characterized by the constant and progressively increasing number of trypanosomes in the peripheral blood stream, by the usual lack of any clinical manifestations, and by the relatively early death of the infected animal. An effective therapeutic compound, therefore, for the treatment of trypanosomiasis of mice and rats must be biologically available within a very short time after its administration and must have a sufficient speed and duration of action to halt and eventually overcome a rapidly increasing blood infection comparable, in part, with a bacteriemia, which if not checked, will cause the death of the animal in a few days or even hours. On the other hand, trypanosomiasis of many of the larger animals, especially of the rabbit, is preeminently a tissue infection and is characterized, in the acute stages, by conspicuous edematous and inflammatory swellings of the soft parts, particularly of the head and external genitalia, together with loss of appetite, weakness, and emaciation, while in the more chronic phases of the infection, the inflammatory lesions undergo induration and even necrosis with involvement of the deeper tissues including the periosteum and bone. The duration of the infection in rabbits is a matter of weeks or months and the presence or absence of trypanosomes in the blood stream is distinctly of minor importance. It is obvious that a drug which is used for the treatment of this type of infection must possess in addition to trypanocidal action, the power of penetrating diseased tissue, and since this may require a considerable amount of time, the drug in question must remain biologically active in the animal host as long as may be necessary.
In order, therefore, to arrive at a full appreciation of the therapeutic action of a drug in experimental trypanosomiasis, one has, from the point of view of the animal factor, two general types of infection, the treatment of which will furnish information as to the speed of action on the one hand and as to the duration of action or potency of the drug on the other. This information, which should include such data as the determination of a therapeutic range in different animal species as well as curative doses, the therapeutic action against different species of trypanosomes, the comparative value of different routes of administration, and the results of a repeated dose system of therapy, together with the data upon the toxicological and pathological action of the drug in question in various animal species, furnishes a logical foundation for an accurate appraisal of the action of the drug under experimental laboratory conditions and, at the same time, furnishes a basis for estimating its probable value in the treatment of trypanosomal infections as they occur in nature.
The present paper includes the therapeutic results obtained with the amide of N-phenylglycine-p-arsonic acid in experimental trypanosomiasis of mice, rats, and guinea pigs. While trypanosomiasis of guinea pigs is, strictly speaking, a chronic infection of cyclic character, the results of its treatment with this drug are incorporated with those of acute infections of mice and rats.
EXPERIMENTAL. Tr. brucd, Tr. gambiense, Tr. equinum, Tr. equiperdum, and Tr. evansi, carried constantly in stock mice and stock guinea pigs, were used for the infecting organisms, and all inoculations were made intraperitoneally. The details of animal inoculation for therapeutic purposes and the general conduct of such experiments have been de-scribed 1 and need not be repeated here; but in this connection, mention may be made of the desirability of regulating and maintaining a uniform grade of infection, a factor of importance in interpreting therapeutic results. In the majority of experiments, we used a strain of Tr. brucei which is highly virulent and uniformly fatal for mice, rats, and guinea pigs, mice dying in from 60 to 70 hours, rats in from 4 to 5 days, and guinea pigs on an average of 4 weeks after the usual intraperitoneal inoculation. With organisms of less virulence, the size of the inoculating dose was proportionately adjusted to insure an infection comparable with that produced by our strain of Tr. brucei. 2 Both mice and rats were treated 18 to 24 hours and guinea pigs usually 1 week after inoculation, after parasites had been demonstrated in the peripheral blood. All the untreated controls died irrespective of the species of trypanosome used. Daily examinations of the blood were made in the mouse experiments for the 1st week or 10 days and at frequent intervals thereafter, while with rats and guinea pigs, the examinations usually began with 2 day intervals. The treated animals were kept under observation from 1 to 3 months. Doses of the drug used are expressed in grams of the sodium salt per kilo of body weight. The solutions were always freshly prepared with sterile distilled water in various concentrations (0.5, 1, and 2 per cent) and the intraperitoneal route of administration was usually employed. The concentration of the drug solution in any given experiment remained a constant, the volume of the dose being the variable quantity.
Strains of

Treatment of Experimental Trypanosomiasis of Mice.
For convenience of comparison, we have summarized, in the accompanying tables, the various protocols of individual experiments which were undertaken for the purpose of ascertaining the range of therapeutic action of the drug. We have included under the heading "intercurrent deaths" those animals which died from accidental 1 Pearce, L., and Brown, W. H., J. Exp. Med., 1918, xxviii, 109. 2 In the case of Tr. equinum, the infection produced in several mouse and rabbit experiments was of an unusually severe nature, a condition which may be referable to an increase in the virulence of the strain at the time of inoculation or to the strength of the inoculating dose employed.
causes within the first 15 days after treatment in the cases of Tr. brucei, Tr. gambiense, and Tr. equinum, and within the first 30 days in the cases of Tr. equiperdum and Tr. evansi, since it was found that relapses practically always occurred within these periods of time with our strains of these species of trypanosomes, and none of the animals listed under "intercurrent deaths" is included in the number of cured animals irrespective of the size of the dose administered.
Trypanosoma brucei.-- Table I N-phenylglycine-p-arsonic acid ranging from 0.15 to 1 gm. per kilo of body weight administered intraperitoneally. The majority of animals were treated with doses of from 0.2 to 0.3 gm., since doses above this level seemed uniformly curative, and in fact, no relapse was demonstrable with amounts of 0.275 gm. or more. Two mice, one treated with 0.4 gm. and the other with 0.3 gin., died from accidental causes within the first 15 days and consequently were not included in the number of'cured animals, although in neither case could trypano-somes be demonstrated. All the other mice which were treated with doses ranging from 0.275 to 1 gm. showed no relapse and all lived 30 days after treatment. Doses of 0.2, 0.225, and 0.25 gin. per kilo of body weight were found to exert a definite therapeutic action, although at these levels relapses occurred. With 0.25 gm., two out of nineteen mice relapsed and one died from intercurrent causes; with 0.225 gin., three relapses occurred out of thirteen mice; with 0.2 gin., there were eight relapses out of thirteen treated animals. With doses at this level, relapses usually appeared from 3 to 9 days after treatment. In some instances with doses of 0.2 and 0.225 g-re., parasites were never completely cleared from the blood but they were definitely less numerous than in the blood of the untreated controls, and in addition, these mice lived longer than the controls. The number of mice treated intravenously and subcutaneously, shown in Tables II and III , is relatively small, yet the therapeutic results by such routes are in striking accord with those obtained by intraperitoneal administration of the drug. Of eleven mice treated intravenously with doses ranging from 0.025 to 0.6 gm. per kilo, four animals which were given doses of 0.025, 0.05, 0.1, and 0.15 gm. respectively were not cured and the blood of those receiving the three lowest doses was never cleared of parasites, while the mouse which was treated with 0.15 gin. relapsed on the 4th day. Doses of 0.2 gin. and above were uniformly curative as contrasted with the slightly higher level of 0.275 gin. by intraperitoneal administration.
Fourteen mice were treated subcutaneously, as indicated in Table  III , with doses of 0.2, 0.25, and 0.3 gin. with no relapses, although there was one intercurrent death in the first fortnight which is not (Table IV) . There were four demonstrable relapses; one mouse treated with 0.25 gin. relapsed on the llth day, one with 0.15 gin. also on the llth day, and two with 0.125 gin. on the 14th day. Of the fourteen mice which were given doses of 0.125 and 0.15 gin., three died within the first 15 days from accidental causes, three definitely relapsed, and eight animals survived the 30 day period of cure. Graded doses from 0.175 to 0.3 gin. were given to thirty-two mice, and of this number but one animal treated with 0.25 grn. relapsed. The range of therapeutic activity of the amide of N-phenylglycine-p-arsonic acid against Tr. gambiense infection in mice is definitely greater than against Tr. brucei infections, since doses of 0.15 gin. failed to cure nagana mice and doses of 0.2 gm. were curative in but five out of thirteen animals. teen mice treated with these doses were cured, while in some instances, the life of the uncured animal was considerably longer than that of the untreated control. A dose of 0.05 gin. had no effect whatever on the length of the infection or on the number of parasites in the peripheral blood in the single instance in which this dose was used. occurred with all doses used irrespective of size, from 4 to 15 days after treatment, and there were no cures below doses of 0.225 gm., although in every instance, even with the lowest doses, the peripheral blood was cleared of trypanosomes for several days and the mice themselves lived from 2 to 8 days longer than the untreated controls. On the other hand, there were some cures at doses of 0.2 to 0.3 gin.
Trypanosoma equiperdum.--In
Trypanosoma evansi.--Thirty mice infected with Tr. evansi were treated intraperitoneally with the amide of N-phenylglycine-parsonic acid in doses ranging from 0.15 to 0.75 gm. (Table VII) .
There were definite cures at all doses above 0.15 gin. with no demonstrable relapse above 0.5 gin. Of the four mice treated with 0.75 gin., one died within the first 30 days after treatment and three were cured. With doses ranging downward from 0.5 gm., relapses occurred irregularly in from 7 to 15 days, but the trypanocidal activity of the drug was shown in all instances even with the lowest doses, since the blood was cleared of parasites for several days following treatment. 
Treatment of Experimental Trypanosomiasls of Rats.
The therapeutic experiments with rats are likewise grouped in tables according to the various species of trypanosomes employed. As in the case of the mice experiments, the animals listed under "intercurrent deaths" are not included in the number of cured animals, irrespective of the time of occurrence of the death or of the size of the dose administered. Intraperitoneal administration of the drug was employed in every experiment.
Trypanosoma brucei.--Thirty-four rats infected with Tr. brucel were treated intraperitoneally with the amide of N-phenylglycine-parsonic acid in doses of from 0.2 to 1.25 gin. per kilo of body weight (Table VIII) . There was but one demonstrable relapse at 0.225 gin.
in an animal which showed numerous trypanosomes in its blood 14 days after treatment. With doses of the drug as high as 0.75 gin., rats may show an early and severe intoxication from which recovery is unusual, and such was the case with the rat which was treated with 0.9 gin. and which died on the 4th day. Doses below 0.6 gin. are well borne and are uniformly curative in Tr. brucei infections down to 0.25 gin. However, with doses below this level, the therapeutic action of the drug is still marked as shown by the single relapse in five animals treated with 0.2 and 0.225 gm. doses. 
Tr. brucei Infection of Rats Treated with N-Phenylglycineamide-p-Arsonic Acid 24
Hours after Inoculation. Intraperitoneal Administration. 
No, ofcures.
* Two pregnant females dying 7 and 8 days after treatment. Table IX shows the results of the treatment of twenty-five rats infected with Tr. gambiense with doses of from 0.1 to 0.3 gm. Doses of 0.2 gm. and above were uniformly curative, no relapses occurring in the fifteen animals treated with 0.2, 0.25, and 0.3 gm. per kilo of body weight. Ten animals were given 0.1 and 0.15 gm. doses, and of this number, there were three relapses and one accidental death. One rat which was treated with 0.15 gm. showed a well developed blood infection on the 18th day and died on the 25th day after treatment. The two rats which relapsed with doses of 0.1 gm. showed trypanosomes on the 10th and 18th days and died on the 25th and 36th days. Trypanosoma equiperdum.--Eight rats infected with Tr. equiperdum were treated with the amide of N-phenylglycine-p-arsonic acid as shown in Table X . Doses from 0.25 to 0.5 gin. per kilo of body weight were used and no relapse occurred in the higher doses of 0.4 and 0.5 gin. Two rats treated with 0.3 gm. relapsed on the 8th and 16th days and one with 0.25 gin. relapsed on the 7th day. In each case, however, examination of the peripheral blood showed no parasites for several days and the animals all lived longer than the untreated controls. Trypanosoma evansi.--The results of the treatment of surra infectfon in rats are shown in Table XI . Nine rats were treated with doses ranging from 0.25 to 0.5 gin. per kilo of body weight, and no relapses were observed with doses above 0.25 gin. Of the three rats which were given 0.25 gin. of the drug, one relapsed with a heavy blood infection on the 14th day after treatment and died on the following day; a second animal which died on the 14th day showed at autopsy a large splenic tumor and was considered a probable relapse; while the third rat in this group, which died 13 days after treatment, is not counted as a cured animal, although no parasites were found in the peripheral blood and the autopsy findings were negative. 
Trypanosoma gambiense.--
Treatment of Experimental Trypanosomiasis of Guinea Pigs.
A number of therapeutic experiments in guinea pigs have been done of which the example given in Table XII is typical. Doses of 0.15, 0.2, and 0.25 gin. per kilo of body weight of the compound given intraperitoneaUy in a 2 per cent solution were uniformly curative, no relapses having been detected during the period of observation of 3 months. The nagana infection in this particular experiment was severe, as shown by the death of the control animals on the 1st and 3rd days after treatment of the series. Other experiments in which the same and much larger doses of the drug were given showed uniformly curative results and need not be included here.
The therapeutic action of N-phenylglycineamide-p-arsonic acid upon experimental trypanosomiasis of guinea pigs is in striking accord with that obtained in mice and rats and in marked contrast to that of many trypanocidal drugs which show a greatly lessened therapeutic action in this animal species. No. of relapses.
~0. of Cllres.
DISCUSSION.
As has been shown in the accompanying tables, the curative level of the amide of N-phenylglycine-p-arsonic acid is quite constant and uniform for most species of trypanosome infections in both mice and rats. Certain exceptions exist which will be referred to later, but in general, with the more virulent strains of organisms and the grade of infection which we have used, single doses of from 0.2 to 0.3 gin. per kilo of body weight given intraperitoneally 24 hours after inoculation are uniformly curative. The parasites promptly disappear from the peripheral blood within 24 hours following treatment at this level of dosage and barring death from accidental causes, the animals survive the observation period of 1 or 2 months with no return of the infection. For mice the minimum lethal dose of this drug given intraperitoneally has been placed at 2 to 2.25 gin. per kilo of body weight, and since the curative dose may be considered as 0.275 gin., we have a curative ratio of 1:8~ Similarly the minimum lethal dose of the drug for rats has been estimated at 0.75 gm. per kilo of body weight, and the curative ratio for rats, therefore, is 1 : 3.
In addition, the range of therapeutic activity, as indicated by the dose that will temporarily clear the blood of trypanosomes as well as effect a certain proportion of cures, varies somewhat with the species of organism. Generally speaking, with the more virulent and more rapidly fatal trypanosomes, the clearing dose closely approaches the curative dose. Thus, with these strains, doses of 0.15 to 0.25 gm. cleared the blood of trypanosomes for several days, although the curative dose for both strains must be placed above 0.5 gin. The range of therapeutic activity as expressed in the size of the clearing dose is practically the same in the rat as in the mouse infections. Different species of trypanosomes vary considerably in their resistance to therapeutic agents, and in this respect, the therapeutic action of this compound is not maintained at the constant curative level of 0.2 to 0.3 gm. per kilo of body weight. Moreover, the animal species employed may to some extent influence the control of certain infections. The curative range of 0.2 to 0.3 gin. is quite con- relapsed with a 0.25 gin. dose. It is possible that this relapse might have been due to a leakage of the drug at the time of treatment, since this was the only observed relapse in twenty-eight mice treated with doses of from 0.175 to 0.25 gin. The majority of relapses with these infections occurred from 5 to 12 days after treatment. The level of relapse occurrence with Tr. brucei and Tr. gambiense infections in rats is quite comparable with that observed in mice, while the time of occurrence was from 14 to 25 days after treatment. With the less virulent organisms which were used, Tr. equiperdum and Tr. evansi, the therapeutic action of the amide of N-phenylglycinep-arsonic acid is much less clear-cut and regular. Relapses occurred in mice with doses of from 0.15 to 0.5 grn. and in general from 7 to 15 days after treatment. The therapeutic action in rats, however, is more constant and more sharply limited, for with Tr. equiperdum infections, there were no relapses above 0.3 gm. and with Tr. evansi none above 0.25 gin. The relapses with both these species in rats occurred from 8 to 16 days after treatment. It will be recalled that in all the experiments with both mice and rats, and irrespective of the species of trypanosome employed, treatment was given on the day following the inoculation of the animals and that the therapeutic results described above apply to the treatment of a 24 hour infection. The average curative level, the clearing dose, and the number and time of relapses would undoubtedly be affected with any considerable change in the time of treatment.
The therapeutic results in the treatment of experimental trypanosomiasis of guinea pigs, as shown by the low curative dose of 0.15 gin. per kilo of body weight in a severe infection, .are even better than those obtained inthe treatment of mice and rats and are in striking contrast to the action of certain other trypanocidal agents. The curative ratio expressed in fractions of the minimum lethal dose is 1: 10, since the lethal dose for guinea pigs is 1.5 gin. per kilo of body weight given intraperitoneally or subcutaneously.
The rapidity of the trypanocidal action of the amide of N-phenylglyclne-p-arsonic acid on trypanosomiasis of mice, rats, and guinea pigs is quite marked. That is, with curative doses, the drug becomes quickly available after its administration and remains in an active biological state long enough to accomplish its trypanocidal action, for in 18 to 24 hours after the treatment of a 24 hour infection, the peripheral blood is free of parasites. Moreover, with subcurative but clearing doses, a similar speed of trypanocidal action is shown. This speed of trypanocidal activity is operative in both mice and rats, but in the case of our strains of Tr. equiperdum and Tr. evansi, the action is apparently somewhat more drastic in rats. In mice the therapeutic action extends over a wide range of doses and cures are irregularly distributed among the low as well as among the high limits of this range, while treatment of the same infections in rats reveals a more sharply limited therapeutic action. It is of interest in this connection to compare the results of the adm~nlstration of the drug by different routes in the treatment of Tr. brucei infections of mice. By all three routes, intraperitoneal, intravenous, and subcutaneous, the sharpness of therapeutic action is maintained within the curative range and apparently the drug is as available in an active biological state by subcutaneous as by intraperitoneal or intravenous administration. The therapeutic experiments in guinea pigs are too few to admit final analysis, but apparently the rapidity and sharpness of action of the drug likewise obtain in this animal species.
One other point regarding the action of the drug should be mentioned and this is in connection with the general condition of the treated animals. Practically without exception, all the cured animals showed a marked improvement manifested by a gain in weight and by the healthy appearance of their coats which dated from the time of treatment and continued during the period of observation. The cured animals were usually in a better condition than those of the original stock. Rats which were treated with high doses approaching a lethal level and which developed toxic manifestations did not recover, but aside from this evidence of drug toxicity, the treated animals were uniformly in excellent state. The negative autopsy findings in animals that were treated with therapeatic doses of the amide of N-phenylglycine-p-arsonic acid furnish additional corroborative evidence of the non-injurious action of such doses to the host.
CONCLUSIONS.
N-Phenylglycineamide~p-arsonic acid is an agent of marked therapeutic action in the treatment of experimental trypanosomiasis of mice, rats, and guinea pigs. It possesses an average curative range of from 0.2 to 0,3 gin. per kilo of body weight of the sodium salt against a 24 hour infection in mice and rats produced by several species of pathogenic trypanosomes. Since the lethal dose for mice is from 2 to 2.25 gm. and for rats 0.75 gin. per kilo of body weight, we have curative ratios of 1:8 and 1:3 respectively. The curative dose for guinea pigs is 0.15 gin. per kilo of body weight, thus giving a curative ratio of 1: 10. The trypanocidal activity of this compound is relatively rapid in all three animal species, for the peripheral blood is cleared of organisms within 24 hours after its administration, and in addition, the lower limits of the curative range are comparatively sharply defined. Intraperitoneal, intravenous, and subcutaneous routes of administration for all practical purposes may be considered equally efificacious in Tr. brucei infections of mice both as regards the speed of action of the drug and the average curative range. The ,~dministration of the drug in therapeutic amounts in all three animal species is not followed by manifestations of organic or functional injury, but, on the contrary, the genera] physical conclifton of the treated animals shows an immediate and continued marked improvement.
The therapeutic activity in trypanosomiasis of mice, rats, and guinea pigs as evidenced by the relative speed and sharpness of action, together with the curative ratio as expressed in fractions of the minimum lethal dose, and the absence of organic injury or functional disturbance following therapeutic doses are significant and characteristic features of the amide of N-phenylglycine-p-arsonic acid.
